NEW YORK – PeproMene Bio will expand the ongoing Phase I PMB-102 study of its BAFF-R-targeted CAR T-cell therapy PMB-CT01 after showing initial efficacy in seven lymphoma patients, the firm said ...

If regulators clear the application, the firm will begin a Phase I/II trial for RJVA-001 to assess its safety, tolerability, and initial efficacy.

NEW YORK – Cizzle Biotechnology said on Tuesday it has raised £150,000 ($200,635) to support the rollout of its lung cancer early detection test in the UK and other European countries.

Researchers tested the performance of the whole-genome sequencing-based assay head-to-head against ctDNA and ddPCR assays.

Scientists are seeking new grant opportunities, founding their own for-profit ventures, and exploring other approaches to ...

Healthcare Royalty Partners purchased anticipated royalties and milestone payments, and Regenxbio received $150 upfront at closing.

NEW YORK – CRISPR Therapeutics and Sirius Therapeutics have inked a deal valued at up to $95 million to develop and commercialize small interfering RNA therapies, starting with a treatment for ...

Multiple first-in-human trials showed functional and biomarker improvements in early data reported at ASGCT's annual meeting.

The analysis by Ontada tracked testing rates within the US Oncology Network for PD-L1, FGFR2/3, and HER2 biomarkers over 10 ...

Moving forward, the biotech said it will focus its resources on developing treatments for genetic liver diseases and on its partnered programs.

The treatment has been used in a trial to treat children with GM1 gangliosidosis, but if the FDA allows, this would be the ...

In a Phase Ia trial in ovarian cancer, a strong neutralizing antibody response correlated with better disease control and ...